Femara Study in Adjuvant Breast Cancer Reaches Enrollment Milestone
EAST HANOVER, New Jersey-A phase III study to determine overall and disease-free survival of women with early breast cancer who take the aromatase inhibitor Femara (letrozole tablets) vs placebo in the adjuvant setting following 5 years of hormone therapy with tamoxifen (Nolvadex) has completed enrollment of 4,800 postmenopausal women.
EAST HANOVER, New JerseyA phase III study to determine overall and disease-free survival of women with early breast cancer who take the aromatase inhibitor Femara (letrozole tablets) vs placebo in the adjuvant setting following 5 years of hormone therapy with tamoxifen (Nolvadex) has completed enrollment of 4,800 postmenopausal women.
This is one of two Femara adjuvant clinical trials that together will comprise one of the largest evaluations of an aromatase inhibitor in the adjuvant setting, Novartis Oncology said in a press release. The trial is being conducted by the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG MA-17). The second trial is being conducted by the Breast International Group (BIG 1-98). To date, both studies have enrolled more than 10,000 patients.
